☰
  • Home
  • Blog
  • Policy Papers
  • Analysis
  • Report Cards
  • Summits
  • You’re Invited
Logo
  • Blog
  • Policy Papers
  • Report Cards
  • Analysis
  • Summits

Can ICER Put a Price on Asthma Control?

October 17, 2018

The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details.

View the Graphic.

View Social Graphics.

Tags: Cost Value, Respiratory

Categorized in: Analysis

Recent Blog Posts

Why Don’t Insurers Take Obesity Seriously?  June 30, 2022
Feds Poised to Take a Hard Look at Pharmacy Benefit Managers June 28, 2022
Federal Court Upholds West Virginia Law that Reigns in “Bad Drug” Ads June 24, 2022

2020 K Street NW, Suite 505 Washington, DC 20006 (202) 964-2624

About Us Archive

© 2022 Copyright Institute for Patient Access